Moringin alleviates DSS-induced ulcerative colitis in mice by regulating Nrf2/NF-κB pathway and PI3K/AKT/mTOR pathway

•Moringin protects against DSS-induced colitis in mice by inhibiting inflammatory response and repairing intestinal barrier.•Moringin inhibits NF-κB pathway via activating Nrf2 signaling.•Moringin regulates PI3K/AKT/mTOR signaling pathway. in DSS-induced UC mice.•Moringin may be a potential PPAR-γ a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2024-06, Vol.134, p.112241, Article 112241
Hauptverfasser:	Zhang, Tongbo, Zhao, Linxian, Xu, Meng, Jiang, Peng, Zhang, Kai
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Caco-2 Cells Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Colitis, Ulcerative - pathology Colon - drug effects Colon - pathology Dextran Sulfate Disease Models, Animal Humans Inflammation Male Mice Mice, Inbred C57BL Mice, Knockout Moringin NF-E2-Related Factor 2 - genetics NF-E2-Related Factor 2 - metabolism NF-kappa B - metabolism Nrf2/NF-κB Phosphatidylinositol 3-Kinases - metabolism PI3K/AKT/mTOR PPAR-γ Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects TOR Serine-Threonine Kinases - metabolism Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!